

# Sponsor:

Recent Updates in Pediatric and Adolescent Young Adult (AYA) Acute Lymphocytic Leukemia (ALL)

Webinar





### Welcome and Introductions

Franco Locatelli, MD University of Rome IRCCS Ospedale Pediatrico Bambino Gesù of Rome Italy

Patrick A. Brown, MD Johns Hopkins University School of Medicine USA

APTITUDE HEALTH

### Agenda

#### 14 September 2021

Time (BRT)	Торіс	Presenter
5.00 рм – 5.05 рм	Welcome and Introductions	Franco Locatelli, MD, PhD and Patrick Brown, MD
5.05 рм – 5.15 рм	<ul> <li>Current Paradigm and Long-term Toxicities for Pediatric ALL</li> <li>Integration of innovative immunotherapies</li> <li>Role of MRD in treatment</li> <li>Long-term toxicities</li> </ul>	Franco Locatelli, MD, PhD
5.15 рм – 5.25 рм	<ul> <li>CAR T Cells for Pediatric/AYA ALL</li> <li>Benefits and risks of CAR Ts and bispecifics</li> <li>Role of MRD in research and treatment</li> <li>AYA considerations</li> </ul>	Franco Locatelli, MD, PhD
5.25 рм – 5.40 рм	<ul> <li>Bispecifics for Pediatric/AYA ALL</li> <li>Review of trial results in pediatric/AYA ALL</li> <li>Role of MRD in research and treatment</li> <li>AYA considerations</li> </ul>	Patrick Brown, MD
5.40 рм – 6.00 рм	Questions to Experts	Franco Locatelli, MD, PhD and Patrick Brown, MD





### Current Paradigm and Long-Term Toxicities for Pediatric ALL

Franco Locatelli, MD University of Rome IRCCS Ospedale Pediatrico Bambino Gesù of Rome Italy







### **Current Paradigm for Treatment of Pediatric ALL**

#### Franco Locatelli, MD Università Sapienza, Roma Dept. Pediatric Hematology/Oncology and Cell/Gene Therapy IRCCS Ospedale Bambino Gesù, Roma, Italy



### DISCLOSURES

Name of Company	Research support	Employee	Consultant	Słockholder	Speaker's Bureau	Advisory Board	Other
Miltenyi					Х		
Bellicum	X				X	X	
Amgen					X	Х	
Medac					X		
Neovii					Х	х	
Novartis						X	
Sanofi						X	
Gilead					x		
BluebirdBio					X		

#### Outcome of contemporary trials involving children and adolescents with ALL

Research Group	Trial	Reference	Region	Years	Subgroup	No. of Patients	Event-free Survival†	Overall Survival†	
							per	percent	
COG	Many trials	Hunger et al. <sup>37</sup>	United States, Canada, Australia, New Zealand	2000–2005	All patients B-cell ALL T-cell ALL	6994 5845 457	N/A N/A N/A	91.3 92.0 81.5	
SJCRH	Total Therapy Study XV	Pui et al. <sup>56</sup>	United States	2000–2007	All patients B-cell ALL T-cell ALL	498 422 76	85.6 86.9 78.4	93.5 94.6 87.6	
DFCI	DFCI ALL Consortium Protocol 00–01	Vrooman et al.57	United States, Canada	2000–2004	All patients B-cell ALL T-cell ALL	492 443 49	80.0 82.0 69.0	91.0 N/A N/A	
AIEOP-BFM	AIEOP-BFM ALL 2000	Conter et al., <sup>49</sup> Schrappe et al. <sup>50</sup>	Western Europe	2000–2006	All patients B-cell ALL T-cell ALL	4480 4016 464	80.3 80.4 75.9	91.1 91.8 80.7	
MRC-NCRI	UKALL 2003	Vora et al. <sup>58</sup>	United Kingdom	2003–2011	All patients B-cell ALL T-cell ALL	3126 2731 388	87.2 N/A N/A	91.5 N/A N/A	
DCOG	DCOG Protocol ALL-9	Veerman et al. <sup>59</sup>	The Netherlands	1997–2004	All patients B-cell ALL T-cell ALL	859 701 90	81 82 72	86 N/A N/A	
EORTC CLG	EORTC CLG 58591	Domenech et al.60	Belgium, France	1998–2008	All patients	1940	82.6	89.7	
NOPHO	ALL-2000	Schmiegelow et al. <sup>61</sup>	Denmark, Finland, Iceland, Norway, Sweden	2000–2007	All patients B-cell ALL T-cell ALL	1023 906 115	79 81 64	89 91 72	

\* Infants younger than 1 year of age were excluded from these studies when possible. AIEOP denotes Italian Association of Pediatric Hematology and Oncology, BFM Berlin–Frankfurt– Münster, DCOG Dutch Childhood Oncology Group, DFCI Dana–Farber Cancer Institute, EORTC CLG European Organization for Research and Treatment of Cancer–Children's Leukemia Group, MRC-NCRI Medical Research Council–National Cancer Research Institute, N/A not available, NOPHO Nordic Society of Paediatric Haematology and Oncology, SJCRH St. Jude Children's Research Hospital, and UKALL Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia Trial. † Survival percentages shown are the rates at 5 years except for the rates for the AIEOP-BFM trial, which were reported at 7 years.


#### Hunger SP and Mullighan CG N Engl J Med 2015;373:1541-52 Teachey DT and Pui CH Lancet Oncolo.2019: 20(30):142-154



### **Perspectives for new trials in ALL**

- Utilize novel genetic approaches
- Improve risk stratification by wider combination of genetic factors and response (MRD)
- Avoid additional toxic agents in most patients
- Introduce novel agents under controlled conditions

#### A novel TCF3-HLF fusion in ALL with a t(17;19)(q22;p13)



#### JOURNAL OF CLINICAL ONCOLOGY

#### ORIGINAL REPORT


#### *IKZF1*<sup>plus</sup> Defines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Martin Stanulla, Elif Dagdan, Marketa Zaliova, Anja Möricke, Chiara Palmi, Giovanni Cazzaniga, Cornelia Eckert, Geertruy te Kronnie, Jean-Pierre Bourquin, Beat Bornhauser, Rolf Koehler, Claus R. Bartram, Wolf-Dieter Ludwig, Kirsten Bleckmann, Stefanie Groeneveld-Krentz, Denis Schewe, Stefanie V. Junk, Laura Hinze, Norman Klein, Christian P. Kratz, Andrea Biondi, Arndt Borkhardt, Andreas Kulozik, Martina U. Muckenthaler, Giuseppe Basso, Maria Grazia Valsecchi, Shai Izraeli, Britt-Sabina Petersen, Andre Franke, Petra Dörge, Doris Steinemann, Oskar A. Haas, Renate Panzer-Grümayer, Hélène Cavé, Richard S. Houlston, Gunnar Cario, Martin Schrappe, and Martin Zimmermann, for the TRANSCALL Consortium and the International BFM Study Group


DOI: https://doi.org/10.1200/JCO.2017. 74.3617

### New prognostic pattern: Definition of *IKZF1*<sup>plus</sup>


- Deletion of *IKZF1* and
  - PAX5 and/or
  - CDKN2A and/or
  - CDKN2B and/or
  - CRLF2 (PAR) and
  - Negativity for ERG deletion



### **IKZF1**<sup>plus</sup> and MRD: Impact on EFS



A: MRD – Standard risk (MRD neg at 5w and 12w)
B: MRD – Intermediate risk (MRD non SR/HR)
C: MRD – High risk (MRD pos ≥10<sup>-4</sup> at 12w)




Stanulla M, et al. J Clin Oncol. 2018.

#### AlloHSCT indications in HR pB-ALL in AlEOP-BFM ALL 2017

			PCR-N	IRD results			
	2017			MRD-HR			
	2017	MRD-SR	MRD-MR	MRD TP2 = level 10 <sup>-3</sup>	MRD TP2 ≥ level 10 <sup>-2</sup>		
	TCF3-HLF	MMD	MMD	MMD	MMD		
	no CR d33	no	MD	MMD	MMD		
rchica	t(4;11)	no	MD	MD	MMD		
hiera	hypodiploidy < 44 chr.	no	MD	MD	MMD		
criteria hierarchical	IKZF1 <sup>plus</sup> and FCM d15 ≥10%	no	MD	MD	MMD		
U U	IKZF1 <sup>plus</sup> and FCM d15 <10%	n.a.*	no	MD	MMD		
	FCM d15 ≥10% only	no	no	MD	MMD		
none	of the above features	n.a.*	n.a.*	MD	MMD		

\*treated in non-HR

#### **Class of Kinase rearrangements and therapeutic targets in Ph-like ALL**




\*Several ABL1-class and JAK kinases are rearranged to multiple fusion partners. Abbreviations: ALL, acute lymphoblastic leukaemia; Ph-like, Philadelphia chromosome-like. From the New England Journal of Medicine, Roberts, K. G. et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. **371**, 1010. Copyright © (2014) Massachusetts Medical Society. Reprinted with permission.



Roberts KG & Mullighan CG Nat Rev Clin Onc 201

#### EBF1-PDGFRB (Ph-like) responds to TKI



# Identification of new high-risk groups and reducing relapses in high-risk patients


High-risk criteria	MLL-AF4+						
gh-ris	"MRD-HR" "MRD-MRD SER"						
Hi	"FCM-MRD d15 HR"						
	Hypodiploidy						
	TCF3-HLF +						
	IKZF1plus and PCR- MRD at TP1 positive or inconclusive						
		1986	1990	1995	2000	2009	2017

#### **Studies ALL-BFM**

More and more patients with "intermediately unfavorable" outcome have been identified and shifted to the high-risk arm

# Identification of new high-risk groups and reducing relapses in high-risk patients


 $\rightarrow$  In AIEOP-BFM ALL 2009, the HR group comprised >20% of the patients



Studies ALL-BFM

### AIEOP-BFM ALL 2009 – Interim analysis of the HR group


1391 patients



### The essentials in pediatric ALL: Risk stratification and frontline therapy

- Approximately, 80% 5-year EFS can be achieved in unselected populations of pediatric patients
- The early treatment response in particular through MRD detection has been established to be the strongest prognostic factor
- Translation of novel molecular findings into improved treatment outcome is under investigation in various trials
- New molecular subgroups have been described (eg, Ph-like or *BCR/ABL*-like pB-ALL) and their prognostic role defined
- Novel treatment approaches based on immunotherapy; evidence regarding long-term benefit is yet to be established
- Reduction of long-term toxicities, especially in adolescents, is a priority

#### New immunological approaches under investigation in childhood ALL



Adapted from Bhojw ani D, Pui CH. Lancet Oncol. 2013;14:e205-e217.

### **AIEOP-BFM ALL 2017**

### International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

Randomized phase III study conducted by the AIEOP-BFM study group


EudraCT Number: 2016-001935-12


Sponsor: Universitätsklinikum Schleswig-Holstein, Campus Kiel

### **New in trial AIEOP-BFM ALL 2017**

- Modified workflow and timing in genetic diagnostics
- Genetic profiles and early MRD response may be combined to characterize previously not identified pts at high risk to relapse, eg, *IKZF1*<sup>plus</sup>
- Randomized evaluation of blinatumomab in *de novo* ALL in all non-SR patients
- Selective addition of novel agents in HR group
- Limitation of pCRT (only if age ≥4y, only if CNS-3, and/or if T-ALL with WBC ≥100K)
- TDM for ASP activity only in reintensification (P-II, P-III, HR-1/2/3)


#### **AIEOP-BFM ALL 2017: Treatment overview**





#### AIEOP-BFM ALL 2017: pB-ALL Approach for HR patients: Randomization HR

Can the pEFS be improved by a treatment concept including two cycles of postconsolidation immunotherapy with Blinatumomab (15  $\mu$ g/m<sup>2</sup>/d for 2 x 28 days) replacing two conventional highly intensive chemotherapy courses?




**Expected effects by novel post-consolidation therapy in HR patients:** 

- Significant reduction of toxicity
- Overcoming resistance to chemotherapy in patients with insufficient response to earlier treatment elements

### A brief focus on adolescents

**Acute and late toxicities** 




Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10–14 years as compared with those aged 15–17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study

European Journal of Cancer 122 (2019) 61-71

#### ADOLESCENT AND YOUNG ADULT MALIGNANT HEMATOLOGY

### Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?

Nicolas Boissel<sup>1,2</sup> and André Baruchel<sup>2,3</sup>






### Late effects of treatment in ALL

- Second malignancies
- Osteonecrosis
- Neurocognitive sequelae
- Cardiomyopathy
- Insulin-dependent diabetes (pancreatitis)
- Chronic GvHD
- Chronic immune deficiency (CD19-directed CAR T cells)

Correspondence: Osteonecrosis in childhood acute lymphoblastic leukemia: a retrospective cohort study of the Italian Association of Pediatric Haemato-Oncology (AIEOP)


Parasole et al. Blood Cancer Journal (2018)8:115

#### a. Overall incidence in the age groups



### Published constructs of 2nd generation CD19 CARs for ALL

CAR design important for persistence and sustained efficacy



Del Bufalo F & Locatelli F. Expert Review of Clinical Immunology 2019

### Published studies of 2nd generation CD19 CAR-T cells for r/r ALL

Reference	Treated patients (n)	CAR vector	Response + consolidation
Maude SL, et al.	30	FMC63-41BB-ζ	27 CR; 22 MRD-negative
N Engl J Med 2014;371:1507–17	(18 post-HSCT)	lentivirus	3 → allogeneic HSCT
Lee DW, et al.	20	FMC63-CD28-ζ	<ul> <li>13 CR + 1 CRi; 12 MRD-negative</li> <li>10 → allogeneic HSCT</li> </ul>
Lancet 2015;385:517–28	(7 post-HSCT)	retrovirus	
Gardner RA, et al.	43	FMC63-41BB-ζ	41 CR; 41 MRD-negative
Blood 2017;129:3322–31	(28 post-HSCT)	lentivirus	11 → allogeneic HSCT
<b>Maude SL, et al.</b>	75	FMC63-41BB-ζ	61 CR/CRi; 61 MRD-negative
N Engl J Med 2018;378:439–48	(46 post-HSCT)	lentivirus	8 → allogeneic HSCT
<b>Turtle CJ, et al.</b>	30	FMC63-41BB-ζ	29 CR; 25 MRD-negative
J Clin Invest 2016;126:2123–38	(11 post-HSCT)	lentivirus	13 → allogeneic HSCT
<b>Park JH, et al.</b>	53	SJC25C1-CD28-ζ	44 CR; 32 MRD-negative
N Engl J Med 2018;378:449–59	(19 post-HSCT)	retrovirus	17 → allogeneic HSCT

• 251 patients treated: 85% CR, 76% MRD-negative




#### Summary of ELIANA study

#### ORIGINAL ARTICLE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

- 92 patients enrolled, 75 treated •
- 73% Grade 3-4 AEs related to CAR-T: .
- $81\% \rightarrow CR/CRi$ , all MRD negative; 66% in intention-to-treat analysis .
- 1 year EFS at 50%, no relapses after this •
- Demonstrates feasibility of delivery in multiple centres •





о.	at	Risk	
		امرين سيرم	7


No. at Risk												
Overall survival	75	72	64	58	55	40	30	20	12	8	2	0
Event-free survival	75	64	51	37	33	19	13	8	3	3	1	0

Maude SL, et al. N Engl J Med 2018;378:439-48;

KYMRIAH<sup>™</sup> (tisagenlecleucel) Prescribing Information. Novartis Pharmaceuticals Corporation.




### **Results: Event-Free and Overall Survival**



#### 34 (16.1%) patients went on to HSCT after tisagenlecleucel while in remission

EFS, event-free survival; HSCT, hematopoietic stem cell transplant; OS, overall survival. Pasquini MC, et al. *Blood Adv.* 2020;4:5414-5424.

### **Current Limitations of CAR T Cells**



# CD19-CAR\_Lenti: peculiarities

Viral platform	Lentivirus
Viral supernatant	Provided by Miltenyi Biotec
Reagents	Granted by Miltenyi Biotec at reduced costs
Production	Automated (CliniMACS Prodigy®)
Starting material	Fresh apheresis (0.75-1.5 x 10 <sup>9</sup> total WBC)
	CD4/CD8 enriched cells (20-200 x 10 <sup>6</sup> cells)
Release	Fresh drug product
Time between apheresis and lymphodepletion	9 days
Time between apheresis and infusion	14 days




# **Patients characteristics**

Pt ID	Gender	Age (y)	Cytogenetic anomalies	Disease phase at infusion	Previous allogeneic HSCT	BM blasts at lymphodepletion
001	Μ	7	None	ALL 2 <sup>nd</sup> relapse	Νο	8,9%
002	F	5	None	ALL 3 <sup>rd</sup> relapse	Yes	15,7%
003	F	7	47, XX (+21)	ALL 1 <sup>st</sup> very early relapse	Νο	2,8%
004	М	4	None	ALL 2 <sup>nd</sup> relapse (combined BM+CNS)	Yes	0,6%
005	Μ	12	t(1;19)	ALL 1 <sup>st</sup> refractory relapse (combined BM + bone and kidney)	Νο	2,3%
	001 002 003 004	001       M         002       F         003       F         004       M	Pt ID         Gender         (y)           001         M         7           002         F         5           003         F         7           004         M         4	Pt ID         Gender         (y)         anomalies           001         M         7         None           002         F         5         None           003         F         7         47, XX (+21)           004         M         4         None	Pf IDGender(y)anomaliesinfusion001M7NoneALL 2 <sup>nd</sup> relapse002F5NoneALL 3 <sup>rd</sup> relapse003F747, XX (+21)ALL 1 <sup>st</sup> very early relapse004M4NoneALL 2 <sup>nd</sup> relapse (combined BM+CNS)005M12t(1;19)ALL 1 <sup>st</sup> refractory relapse (combined BM +	Pt IDGender(y)anomaliesinfusionallogeneic HSCT001M7NoneALL 2 <sup>nd</sup> relapseNo002F5NoneALL 3 <sup>rd</sup> relapseYes003F747, XX (+21)ALL 1 <sup>st</sup> very early relapseNo004M4NoneALL 2 <sup>nd</sup> relapse (combined BM+tCNS)Yes005M12t(1;19)ALL 1 <sup>st</sup> refractory relapse (combined BM +terpseNo



# **CAR\_Lenti expansion and outcome**





# **Final considerations**

- Treatment of childhood ALL is becoming more and more complex and sophisticated over time, integrating genetic data and MRD response in patient stratification;
- The goal is that of curing more and better, sparing side effects while maintaining and even improving the high cure rate we have achieved so far;
- Immunotherapy is changing the therapeutic scenario of childhood B-ALL;
- Ongoing studies will define its role in newly diagnosed patients.





# **Bispecifics for Pediatric/AYA ALL**

Patrick A. Brown, MD Johns Hopkins University School of Medicine USA







THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER




NCCN Network®

# **Bispecifics for Pediatric/AYA ALL**

#### Patrick Brown, MD

Professor of Oncology, Johns Hopkins University Director, Pediatric Leukemia Program, Sidney Kimmel Comprehensive Cancer Center Vice Chair for Relapse, COG ALL Committee Chair, NCCN ALL Guidelines Panel

### **Mechanism: Normal vs BiTE vs CAR vs ADC**





### Background

- Poor survival for 1<sup>st</sup> relapse B-ALL in children, adolescents and young adults (AYA), especially early relapses
- Standard treatment approach
  - Reinduction chemotherapy  $\rightarrow 2^{nd}$  remission
  - Consolidation
    - <u>Early relapse</u>: Intensive chemo  $\rightarrow$  HSCT
      - Goal: MRD-negativity prior to HSCT
    - Late relapse

CHILDREN'S ONCOLOGY GROUP

- "MRD high": same as early
  - "MRD low": Intensive chemo  $\rightarrow$  maintenance therapy





### Blinatumomab (CD19 BiTE)

- In multiple relapsed/refractory setting (peds and adults)
  - CR 40%-45%
  - MRD-negative CR 20%–35%
  - Early survival benefit (adults)

von Stackelberg et al. *J Clin Oncol.* 2016;34:4381-4389 Kantarjian et al. *N Engl J Med.* 2017;376:836-847

- In MRD+setting (adults)
  - 80% MRD clearance
  - 60% subsequent DFS (bridge to HSCT)

Gokbuget et al. Blood. 2018;131:1522-1531

CHILDREN'S ONCOLOGY GROUP

AALL1331

12/19/2019

Activated: 12/08/14 Closed: 09/30/19 Version Date: Amendment

idment #10A

CHILDREN'S ONCOLOGY GROUP

AALL1331

Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC# 765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)


IND Sponsor for Blinatumomab: DCTD, NCI

#### STUDY CHAIR


Patrick Brown, MD 1650 Orleans Street, CRB1 RM 2M49 Baltimore, MD. 21231 Phone: (410) 614-4915 Fax: (410) 955-8897 E-mail: pbrown2@jhmi.edu

#### Overall objective of COG AALL1331:

CHILDREN'S ONCOLOGY GROUP To determine if substituting blinatumomab for intensive consolidation chemotherapy improves survival in first relapse of childhood/AYA B-ALL



### Survival: Arm A (chemotherapy) vs Arm B (blinatumomab)




CHILDREN'S ONCOLOGY GROUP

#### Median follow up 2.9 years

Brown P, et al. JAMA. 2021;325(9):833-842.


### **Results AYA Patients (Ages 18–30 at Relapse)**



CHILDREN'S ONCOLOGY GROUP

#### Median follow up 1.4 years

### **Other Endpoints: MRD, AEs, HSCT Bridging**



Significant contributors to the improved outcomes for Arm B (blina) vs Arm A (chemo) in HR/IR relapses may include better **MRD clearance, less toxicity and greater ability to successfully bridge to HSCT** 

CHILDREN'S ONCOLOGY GROUP

Brown P, et al. JAMA. 2021;325(9):833-842.

### Amgen 20120215: Open-Label, Randomized, Phase III Trial: 47 Centers, 13 Countries

#### Key eligibility criteria


- Age >28 days <18 years
- HR 1st relapse Ph- BCP-ALL
- M1 or M2 marrow at randomization
- No CNS disease, unless treated before enrollment
- No clinically relevant CNS pathology

#### **Stratification**

- Age: <1 year, 1 to 9 years, >9 years
- BM status at end of HC2
  - M1 with MRD >10<sup>-3</sup>
  - M1 with MRD <10<sup>-3</sup>
  - M2

#### **Endpoints**


- Primary: EFS
- Secondary
  - OS
  - MRD response (end of blinatumomab or HC3)
  - Cumulative incidence of relapse
  - Incidence of AEs
  - Survival 100 days post HSCT



Locatelli F, et al. JAMA. 2021;325(9):843-854.

BCP, B-cell precursor; EFS, event-free survival; HC, high-risk consolidation.


### Superior EFS in the Blinatumomab Arm



Locatelli F, et al. JAMA. 2021;325(9):843-854.


P, stratified log rank P value; HR, hazard ratio from stratified Cox regression.

# Superior MRD Remission by PCR in the Blinatumomab Arm (overall and by baseline<sup>\*</sup> MRD status)



Locatelli F, et al. JAMA. 2021;325(9):843-854.

\*Baseline: end of HC2 (screening sample before enrollment) PCR, polymerase chain reaction




CHILDREN'S ONCOLOGY GROUP

\*UKALLR3 reference: Parker et al. Lancet. 2010;376:2009-2017.

### What Happens When Blinatumomab Doesn't Work?

Endogenous T-cell "exhaustion"




#### Role for immune checkpoint inhibitors (eg, anti–PD-1)?

PD-1	PD-L1	CTLA-4
Nivolumab	Atezolizumab	lpilimumab
Pembrolizumab*	Avelumab	
	Durvalumab	

### Reports of efficacy in patients relapsing after blina/CAR T-cells

\* Feucht, et al. *Oncotarget*. 2016;7(47):76902-76919

### AALL1821: Blinatumomab + Nivolumab



### Can We Predict When Blinatumomab Won't Work?



Correspondence 🔂 Free Access


### Day 15 bone marrow minimal residual disease predicts response to blinatumomab in relapsed/refractory paediatric B-ALL

Patrick Brown 🔀, Gerhard Zugmaier, Lia Gore, Catherine A. Tuglus, Arend von Stackelberg

First published: 03 December 2019 | https://doi.org/10.1111/bjh.16306

### **Biomarkers to Predict Blinatumomab Success/Failure**


- Study definitions
  - "Success" was defined as complete MRD response in CR (n = 14)
  - "Failure" was defined as anything other than success (n = 50)
- Overall, Day 15 MRD results predicted best response after 2 cycles with 95% accuracy (correctly in 56 of 59 patients)




As patients with MRD  $\geq 10^{-4}$  at Day 15 could potentially pursue alternative therapies. such as dose escalation or combination therapies, **Day 15** MRD results may allow personalized treatment and improve outcomes in pediatric patients with relapsed/refractory B-ALL

### Clinical Trial Questions in COG: Molecularly/Immunologically Targeted Therapy in B-ALL

	Risk Group	Projected 5-yr DFS	Therapeutic Question		
33%	SR-Favorable	>95%	Standard therapy with 2 year duration of maintenance therapy for boys and girls		AALL1731
2%	HR-Favorable	>94%			AALL1732
32%	SR-Avg & High	~89%	Blinatumomab	ad a	AALL1731
27%	High Risk	~80%	Inotuzumab		AALL1732
2%	Very High Risk	<50%	CAR T-cell therapy		AALL1721
5%	Ph+, Ph-like	60-85%	Molecularly targeted therapy		AALL1631 & 1521






### **Blinatumomab: Questions and Discussion**

- HSCT after MRD clearance with blinatumomab?
- Role of HTS (ClonoSEQ) MRD?
- Ability of checkpoint inhibition to safely enhance blinatumomab response?
- Earlier (pre-treatment) predictive biomarkers of blinatumomab response?
- Risk of prior blinatumomab exposure and CD19 escape after subsequent CD19 CAR T therapy?






# Questions to the Experts





#### Platinum Sponsor:





## Closing

Franco Locatelli, MD University of Rome IRCCS Ospedale Pediatrico Bambino Gesù of Rome Italy

Patrick A. Brown, MD Johns Hopkins University School of Medicine USA

APTITUDE HEALTH

# Thank you to all participants!

And thank you to Amgen for their sponsorship

> Please complete the evaluation form using the provided link

To obtain a copy of the meeting slides and access other educational materials, please visit the GLA website at: <u>www.globalleukemiaacademy.com</u>

- Meeting materials will be available in approximately 1 week

If you have a question for any of our experts that was not answered today, you can submit it through the GLA website at: <u>https://globalleukemiaacademy.com/ask-the-expert/</u>





APTITUDE HEALTH

Recent Updates in Pediatric and Adolescent Young Adult (AYA) Acute Lymphocytic Leukemia (ALL)

Webinar

Sponsor:

Platinum

